SEC Comment Letter for Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306) (ARQT) — Feb 5, 2024

Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306)
Date: Feb. 5, 2024 · CIK: 0001787306 · Accession: 0000000000-24-001405

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-276794

Date

February 5, 2024

Author

Todd Franklin Watanabe

Form

UPLOAD

Company

Arcutis Biotherapeutics, Inc. (ARQT) (CIK 0001787306)

Letter

United States securities and exchange commission logo February 5, 2024 Todd Franklin Watanabe President and Chief Executive Officer Arcutis Biotherapeutics, Inc. 3027 Townsgate Road, Suite 300 Westlake Village, California 91361 Re:Arcutis Biotherapeutics, Inc. Registration Statement on Form S-3 Filed January 31, 2024 File No. 333-276794 Dear Todd Franklin Watanabe: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ross McAloon

Show Raw Text

United States securities and exchange commission logo
February 5, 2024
Todd Franklin Watanabe
President and Chief Executive Officer
Arcutis Biotherapeutics, Inc.
3027 Townsgate Road, Suite 300
Westlake Village, California 91361
Re:Arcutis Biotherapeutics, Inc.
Registration Statement on Form S-3
Filed January 31, 2024
File No. 333-276794
Dear Todd Franklin Watanabe:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Ross McAloon

SecProbe.io